1. Home
  2. NMRA vs LPAA Comparison

NMRA vs LPAA Comparison

Compare NMRA & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • LPAA
  • Stock Information
  • Founded
  • NMRA 2019
  • LPAA 2024
  • Country
  • NMRA United States
  • LPAA United States
  • Employees
  • NMRA N/A
  • LPAA N/A
  • Industry
  • NMRA
  • LPAA
  • Sector
  • NMRA
  • LPAA
  • Exchange
  • NMRA Nasdaq
  • LPAA Nasdaq
  • Market Cap
  • NMRA 121.0M
  • LPAA 299.9M
  • IPO Year
  • NMRA 2023
  • LPAA 2024
  • Fundamental
  • Price
  • NMRA $1.26
  • LPAA $10.40
  • Analyst Decision
  • NMRA Buy
  • LPAA
  • Analyst Count
  • NMRA 8
  • LPAA 0
  • Target Price
  • NMRA $9.29
  • LPAA N/A
  • AVG Volume (30 Days)
  • NMRA 1.6M
  • LPAA 66.6K
  • Earning Date
  • NMRA 08-05-2025
  • LPAA 01-01-0001
  • Dividend Yield
  • NMRA N/A
  • LPAA N/A
  • EPS Growth
  • NMRA N/A
  • LPAA N/A
  • EPS
  • NMRA N/A
  • LPAA 0.36
  • Revenue
  • NMRA N/A
  • LPAA N/A
  • Revenue This Year
  • NMRA N/A
  • LPAA N/A
  • Revenue Next Year
  • NMRA N/A
  • LPAA N/A
  • P/E Ratio
  • NMRA N/A
  • LPAA $29.02
  • Revenue Growth
  • NMRA N/A
  • LPAA N/A
  • 52 Week Low
  • NMRA $0.61
  • LPAA $9.66
  • 52 Week High
  • NMRA $17.19
  • LPAA $10.70
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 69.27
  • LPAA N/A
  • Support Level
  • NMRA $0.72
  • LPAA N/A
  • Resistance Level
  • NMRA $1.18
  • LPAA N/A
  • Average True Range (ATR)
  • NMRA 0.10
  • LPAA 0.00
  • MACD
  • NMRA 0.03
  • LPAA 0.00
  • Stochastic Oscillator
  • NMRA 74.14
  • LPAA 0.00

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

About LPAA Launch One Acquisition Corp. Class A Ordinary shares

Launch One Acquisition Corp is a blank check company.

Share on Social Networks: